Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e143-6. doi: 10.1093/jpids/piu104. Epub 2014 Nov 12.

Abstract

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.

Keywords: HPIV-1 vaccine; children; lower respiratory tract illness.

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Adult
  • Antibodies, Viral / blood
  • Child, Preschool
  • Double-Blind Method
  • Humans
  • Infant
  • Parainfluenza Vaccines / therapeutic use*
  • Parainfluenza Virus 1, Human
  • Paramyxoviridae Infections / epidemiology
  • Paramyxoviridae Infections / prevention & control*
  • Vaccines, Attenuated / therapeutic use

Substances

  • Antibodies, Viral
  • Parainfluenza Vaccines
  • Vaccines, Attenuated

Associated data

  • ClinicalTrials.gov/NCT00641017